Rationale and Design of the Study to Investigate the Metabolic Action of Imeglimin on Patients with Type 2 Diabetes Mellitus (SISIMAI)

Authors

Institutions

Publication Details

Journal
Diabetes Therapy
Published
2024-09-30
DOI
https://doi.org/10.1007/s13300-024-01655-x
Citations
1
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.36

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rationale and Design of the Study to Investigate the Metabolic Action of Imeglimin on Patients with Type 2 Diabetes Mellitus (SISIMAI)

Toshiki Kogai, Hitoshi Naito, Tsubasa Tajima, Saori Kakehi et al.
1 citations
Diabetes Therapy
Diabetes Management and Research
0.36
article

Rationale and Design of the Study to Investigate the Metabolic Action of Imeglimin on Patients with Type 2 Diabetes Mellitus (SISIMAI)

Toshiki Kogai, Hitoshi Naito, Tsubasa Tajima, Saori Kakehi, Ryuzo Kawamori, Hirotaka Watada, Yuya Nishida, Hideyoshi Kaga, Naoaki Ito, Yoshifumi Tamura, Satoshi Kadowaki
article en
1 citations

Abstract

No abstract available for this paper.
Diabetes TherapyVol. 15(12)
Juntendo University (JP)
Eli Lilly and Company, Kowa Company, Boehringer Ingelheim Japan, Novo Nordisk, Astellas Pharma, Astellas Foundation for Research on Metabolic Disorders, Eli Lilly Japan, Novo Nordisk Pharma
Good health and well-being
Openalex Percentile: Top 34%
Diabetes Management and Research
0.36
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.